Patents by Inventor Jane C. Stewart

Jane C. Stewart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20100298545
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
    Type: Application
    Filed: November 25, 2009
    Publication date: November 25, 2010
    Inventors: Michael S. Kinch, Kelly Carles-Kinch, Jane c. Stewart
  • EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20100143345
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
    Type: Application
    Filed: June 5, 2009
    Publication date: June 10, 2010
    Applicants: MEDIMMUNE, LLC, PURDUE RESEARCH FOUNDATION
    Inventors: Michael S. Kinch, Kelly Carles-Kinch, Jane C. Stewart
  • EphA2 agonistic monoclonal antibodies and methods of use thereof
    Publication number: 20040091486
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
    Type: Application
    Filed: May 12, 2003
    Publication date: May 13, 2004
    Inventors: Michael S. Kinch, Kelly Carles-Kinch, Jane C. Stewart